The proposed sale is very small relative to the insider's total holdings and market cap. Monitor the insider's Form 4 filings to see if the sale was actually executed; a single small sale by a director is routine and not a signal of deteriorating fundamentals.
LGND drugs
LGND drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 2 $307.02entry
- T+1 · 14d ago +2.12%α +1.82% · $313.52
- T+5 · 8d ago +2.32%α +2.24% · $314.15
- T+10 · todayOpen
- T+20 · in 14d Pending
- T+60 · in 2mo Pending
Price Chart
How similar events traded
Executive Summary
Director Jason Aryeh filed a Form 144 notice of intent to sell 1,209 shares of Ligand Pharmaceuticals common stock, valued at approximately $385,185 based on the filing date. The shares were acquired as restricted stock on June 5, 2026, and the proposed sale is scheduled for October 30, 2026. This is a small, routine sale by a director and carries minimal signal value.
Key Facts
- Jason Aryeh, a Director of Ligand Pharmaceuticals, filed Form 144 to sell 1,209 shares of common stock.
- The approximate market value of the proposed sale is $385,185.
- The shares were acquired as restricted stock on June 5, 2026.
- The proposed sale date is October 30, 2026.
- The sale represents about 0.006% of the company's $6.4B market cap.
Financial Impact
Proposed sale of 1,209 shares valued at approximately $385,185, representing a negligible fraction of the company's market cap.
Risk Factors
- Form 144 is an advance notice of intent to sell; the sale may not be executed.
- No other insider selling pattern or context provided to suggest a pattern.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010515 |
| Document: 0001950047-26-010515-index.html | 0001950047-26-010515 |
| Document: 0001950047-26-010515.txt | 0001950047-26-010515 |
Track record
29 reports on LGND
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.85% at T+60 after the Apr 14, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $305.74 Now $301.71 −1.32% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $306.47 Now $301.71 −1.55% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $316.27 Now $301.71 −4.60% settles Feb 10
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $316.83 Now $301.71 −4.77% settles Feb 9
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $314.16 Now $301.71 −3.96% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $314.15 Now $301.71 −3.96% settles Feb 5
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers